9-Valent human papillomavirus vaccine: a review of the clinical development program

References

• Durzynska J, Lesniewicz K, Poreba E. Human papillomaviruses in epigenetic regulations. Mutat Res. 2017;772:36–50.
   PubMed Web of Science ®Google Scholar
• Bouvard V, Baan R, Straif K, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10:321–322.
   PubMed Web of Science ®Google Scholar
• De Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664–670.
   PubMed Web of Science ®Google Scholar
• Plummer M, De Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:e609–e616.
   PubMed Web of Science ®Google Scholar
• Buck CB, Cheng N, Thompson CD, et al. Arrangement of L2 within the papillomavirus capsid. J Virol. 2008;82:5190–5197.
   PubMed Web of Science ®Google Scholar
• Chen XS, Garcea RL, Goldberg I, et al. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000;5:557–567.
   PubMed Web of Science ®Google Scholar
• De Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–1056.
   PubMed Web of Science ®Google Scholar
• Muñoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–285.
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5:F123–F138.
   PubMed Web of Science ®Google Scholar
• Wigle J, Fontenot HB, Zimet GD. Global delivery of human papillomavirus vaccines. Pediatr Clin North Am. 2016;63:81–95.
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Boily M-C, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15:565–580.
   PubMed Web of Science ®Google Scholar
• Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63:519–527.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137:e20151968.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barre syndrome after human papilloma virus vaccine: a self-controlled case-series study in England. Vaccine. 2017;35:1729–1732.
   PubMed Web of Science ®Google Scholar
• Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906.
   Google Scholar
• Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J. 2010;29:95–101.
   PubMed Web of Science ®Google Scholar
• Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271:193–203.
   PubMed Web of Science ®Google Scholar
• Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29:8279–8284.
   PubMed Web of Science ®Google Scholar
• Gee J, Weinbaum C, Sukumaran L, et al. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016;12:1406–1417.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275:398–408.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, et al. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance. J Autoimmun. 2017;79:84–90.
   PubMed Web of Science ®Google Scholar
• Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012;166:1140–1148.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Eriksson T, Apter D, et al. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: interim analysis of a large community-randomized controlled trial. Hum Vaccin Immunother. 2016;12:3177–3185.
   PubMed Web of Science ®Google Scholar
• Macartney KK, Chiu C, Georgousakis M, et al. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013;36:393–412.
   PubMed Web of Science ®Google Scholar
• Scheller NM, Svanström H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313:54–61.
   PubMed Web of Science ®Google Scholar
• Scheller NM, Pasternak B, Mølgaard-Nielsen D, et al. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes. N Engl J Med. 2017;376:1223–1233.
   PubMed Web of Science ®Google Scholar
• Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750–757.
   PubMed Web of Science ®Google Scholar
• Vichnin M, Bonanni P, Klein NP, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J. 2015;34:983–991.
   PubMed Web of Science ®Google Scholar
• Malagón T, Drolet M, Boily M-C, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781–789.
   PubMed Web of Science ®Google Scholar
• Mesher D, Soldan K, Lehtinen M, et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis. 2016;22:1732–1740.
   PubMed Web of Science ®Google Scholar
• Tanton C, Mesher D, Beddows S, et al. Human papillomavirus (HPV) in young women in Britain: population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017;3:36–41.
   PubMed Web of Science ®Google Scholar
• Woestenberg PJ, King AJ, Van Der Sande MA, et al. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors. J Infect. 2017;74:393–400.
   PubMed Web of Science ®Google Scholar
• Alemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136:98–107.
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199:805–814.
   PubMed Web of Science ®Google Scholar
• Joura EA, Ault A, Bosch FX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23:1997–2008.
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Velicer C, Luxembourg A. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Rev Vaccines. 2015;14:1405–1419.
   PubMed Web of Science ®Google Scholar
• Serrano B, De Sanjosé S, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51:1732–1741.
   PubMed Web of Science ®Google Scholar
• Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol. 1993;67:315–322.
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89:12180–12184.
   PubMed Web of Science ®Google Scholar
• Rose RC, Bonnez W, Reichman RC, et al. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol. 1993;67:1936–1944.
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun XY, Stenzel DJ, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185:251–257.
   PubMed Web of Science ®Google Scholar
• Mach H, Volkin DB, Troutman RD, et al. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci. 2006;95:2195–2206.
   PubMed Web of Science ®Google Scholar
• Shi L, Sings HL, Bryan JT, et al. GARDASIL: prophylactic human papillomavirus vaccine development–from bench top to bed-side. Clin Pharmacol Ther. 2007;81:259–264.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Modis Y, High K, et al. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol J. 2012;9:52.
   PubMed Web of Science ®Google Scholar
• Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 1995;69:3959–3963.
   PubMed Web of Science ®Google Scholar
• Inglis S, Shaw A, Koenig S. Chapter 11: HPV vaccines: commercial research & development. Vaccine. 2006;24 Suppl 3:S3-99-S3105.
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Chandrachud LM, O’Neil BW, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996;219:37–44.
   PubMed Web of Science ®Google Scholar
• Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92:11553–11557.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–265.
   PubMed Web of Science ®Google Scholar
• Ault KA, Giuliano AR, Edwards RP, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine. 2004;22:3004–3007.
   PubMed Web of Science ®Google Scholar
• Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine. 2004;22:2943–2952.
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645–1651.
   PubMed Web of Science ®Google Scholar
• Poland GA, Jacobson RM, Koutsky LA, et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc. 2005;80:601–610.
   PubMed Web of Science ®Google Scholar
• VRBPAC background document: Gardasil HPV quadrivalent vaccine. United States Food and Drug Administration; 2006 [cited 2017 Jan 14. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf
   Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278.
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Four year efficacy of prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine against low-grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;340:c3493.
   Google Scholar
• Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine Gardasil. J Adolesc Health. 2011;49:467–475.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Sigurdsson K, Iversen O-E, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009;2:868–878.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401–411.
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576–1585.
   PubMed Web of Science ®Google Scholar
• Muñoz N, Manalastas RJ, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373:1949–1957.
   PubMed Web of Science ®Google Scholar
• Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135–2145.
   PubMed Web of Science ®Google Scholar
• Dobson SRM, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309:1793–1802.
   PubMed Web of Science ®Google Scholar
• Statistical analysis and evaluation, anal cancer, Gardasil. United States Food and Drug Administration; 2010 cited 2016 Dec 30. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM247722.pdf
   Google Scholar
• Luxembourg A, Brown D, Bouchard C, et al. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother. 2015;11:1313–1322.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen O-E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–723.
   PubMed Web of Science ®Google Scholar
• Huh W, Joura E, Giuliano AR, et al. Efficacy, immunogenicity, and safety of a nine-valent human papillomavirus vaccine in women aged 16–26 years: final analyses of a randomised, double-blind trial. Lancet. 2017. Epub Sep 5.
   PubMedGoogle Scholar
• Castellsagué X, Giuliano AR, Goldstone S, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33:6892–6901.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. 2015;136:e28–e39.
   PubMed Web of Science ®Google Scholar
• Iversen O-E, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA. 2016;316:2411–2421.
   PubMed Web of Science ®Google Scholar
• Billich A. HPV vaccine MedImmune/GlaxoSmithKline. Curr Opin Investig Drugs. 2003;4:210–213.
   PubMedGoogle Scholar
• Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–2170.
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564–571.
   PubMed Web of Science ®Google Scholar
• Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384:2213–2227.
   PubMed Web of Science ®Google Scholar
• Chen YH, Gesser R, Luxembourg A. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clin Trials. 2015;12:84–90.
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Bautista O, Moeller E, et al. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemp Clin Trials. 2015;42:18–25.
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Moreira EDJ, Samakoses R, et al. Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine. Hum Vaccin Immunother. 2015;11:1306–1312.
   PubMed Web of Science ®Google Scholar
• Schilling A, Parra MM, Gutierrez M, et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics. 2015;136:e563–e572.
   PubMed Web of Science ®Google Scholar
• Garland SM, Cheung T-H, McNeill S, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33:6855–6864.
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Mehlsen J, Vesikari T, et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J. 2015;34:627–634.
   PubMed Web of Science ®Google Scholar
• Iwata S, Murata S, Han S, et al. Safety and immunogenicity study of a 9-valent human papillomavirus vaccine administered to 9- to 15-year old Japanese Girls. Jpn J Infect Dis. 2017;70:368–373.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Brodszki N, Van Damme DP, et al. A randomized, double-blind, Phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil® in 9-15-year-old girls. Pediatr Infect Dis J. 2015;34:992–998.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Meijer CJ, Kieninger D, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34:4205–4212.
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Kjaer SK, Nygard M, et al. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine. Contemp Clin Trials. 2017;52:54–61.
   PubMed Web of Science ®Google Scholar
• Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines–immune responses. Vaccine. 2012;30 Suppl 5:F83–F87.
   PubMed Web of Science ®Google Scholar
• Herrero R, González P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16:e206–e216.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). Committee for medicinal products for human use (CHMP), guideline on the choice of the noninferiority margin. EMEA; 2005. Doc Ref. EMEA/EPMP/EWP/21858/99.
   Google Scholar
• Wang WW, Mehrotra DV, Chan IS, et al. Statistical considerations for noninferiority/equivalence trials in vaccine development. J Biopharm Stat. 2006;16:429–441.
   PubMed Web of Science ®Google Scholar
• Hillman RJ, Giuliano AR, Palefsky JM, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol. 2012;19:261–267.
   PubMed Web of Science ®Google Scholar
• Guevara A, Cabello R, Woelber L, et al. Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine. Vaccine. 2017;35:5050–5057.
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics. 2010;125:1142–1151.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Van DP, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J. 2010;29:314–318.
   PubMed Web of Science ®Google Scholar
• Moreira EDJ, Block SL, Ferris D, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 Phase III clinical trials. Pediatrics. 2016;138:e20154387.
   PubMed Web of Science ®Google Scholar
• Rosenblatt M. The large pharmaceutical company perspective. N Engl J Med. 2017;376:52–60.
   PubMed Web of Science ®Google Scholar
• Getz K. Improving protocol design feasibility to drive drug development economics and performance. Int J Environ Res Public Health. 2014;11:5069–5080.
   PubMed Web of Science ®Google Scholar
• Gul RB, Ali PA. Clinical trials: the challenge of recruitment and retention of participants. J Clin Nurs. 2010;19:227–233.
   PubMed Web of Science ®Google Scholar
• Else EA, Swoyer R, Zhang Y, et al. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol. 2011;49:1907–1912.
   PubMed Web of Science ®Google Scholar
• Roberts CC, Swoyer R, Bryan JT, et al. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection. J Clin Microbiol. 2011;49:1899–1906.
   PubMed Web of Science ®Google Scholar
• Dias D, Van DJ, Schlottmann S, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol. 2005;12:959–969.
   PubMedGoogle Scholar
• Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol. 2003;10:108–115.
   PubMedGoogle Scholar
• Smith JF, Kowalski R, Esser MT, et al. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin. 2008;4:134–142.
   PubMed Web of Science ®Google Scholar
• Brown MJ, Seitz H, Towne V, et al. Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58. Clin Vaccine Immunol. 2014;21:587–593.
   PubMed Web of Science ®Google Scholar
• Roberts C, Green T, Hess E, et al. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother. 2014;10:2168–2174.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Leroux-Roels G, Simon P, et al. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Vaccine. 2014;32:3694–3705.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration draft guidance for industry on adaptive design clinical trials for drugs and biologics. United States Food and Drug Administration; 2010 cited 2016 Dec 26. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf
   Google Scholar
• EMA-EFPIA 2nd workshop on adaptive design in confirmatory trials. European Medicines Agency (EMA), European Federation of Pharmaceutical Industries and Associations (EFPIA); 2010 [cited 2016 Dec 26. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2010/04/WC500089206.pdf
   Google Scholar
• Lin M, Lee S, Zhen B, et al. CBER’s experience with adaptive design clinical trials. Ther Innov Regul Sci. 2016;50:195–203.
   PubMed Web of Science ®Google Scholar
• Marshall V, Baylor NW. Food and Drug Administration regulation and evaluation of vaccines. Pediatrics. 2011;127 Suppl 1:S23–S30.
   PubMed Web of Science ®Google Scholar
• Guidance for industry for the evaulation of combination vaccines for preventable disease: production, testing and clinical studies. United States Food and Drug Administration; 1997. Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/UCM175909.pdf.1997
   Google Scholar
• Ganju J, Izu A, Anemona A. Sample size for equivalence trials: a case study from a vaccine lot consistency trial. Stat Med. 2008;27:3743–3754.
   PubMed Web of Science ®Google Scholar
• Sun X, Li X, Chen J. Comments on ‘Sample size for equivalence trials: a case study from a vaccine lot consistency trial’ by J. Ganju, A. Izu and A. Anemona. Stat Med. 2012;31:1652–1653.
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JAJ, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–304.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Markowitz LE, Hariri S, et al. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model. Hum Vaccin Immunother. 2016;12:1363–1372.
   PubMed Web of Science ®Google Scholar
• Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65:1405–1408.
   PubMed Web of Science ®Google Scholar
• Bundesministeriums für Gesundheit und Frauen. Impfplan Österreich 2017; 2017 [cited 2017 Jun 22. Available from: http://www.bmgf.gv.at/cms/home/attachments/2/8/1/CH1100/CMS1452867487477/impfplan.pdf
   Google Scholar
• Updated recommendations on human papillomavirus (HPV) vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule. National Advisory Committee on Immunization (NACI); 2016 cited 2017 Jan 7. Available from: http://www.healthycanadians.gc.ca/publications/healthy-living-viesaine/human-papillomavirus-9-valent-vaccine-update-recommendation-mises-a-jour-recommendations-papillome-humain-vaccin-nonavalent/index-eng.php
   Google Scholar
• Prévention des infections à HPV: place du vaccin Gardasil 9. Haut Conseil de la Santé Publique; 2017 [cited 2017 Jun 22. Available from: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=602
   Google Scholar
• Epidemiologisches bulletin. Robert Koch Institute; 2017 cited 2017 Jun 22. Available from: http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2016/Ausgaben/34_16.pdf?__blob=publicationFile
   Google Scholar
• Norma Nº.016/2016 de 16/ 12/2016. Direção-Geral da Saúde; 2017 [cited 2017 Jun 22. Available from: https://www.dgs.pt/directrizes-da-dgs/normas-e-circulares-normativas/norma-n-0162016-de-16122016.aspx
   Google Scholar
• Chao A, Lin C-T, Hsueh S, et al. Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization. Am J Obstet Gynecol. 2004;190:1046–1051.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus–related disease. Am J Obstet Gynecol. 2004;191:114–120.
   PubMed Web of Science ®Google Scholar
• Sadler L, Saftlas A, Wang W, et al. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA. 2004;291:2100–2106.
   PubMed Web of Science ®Google Scholar
• Giorgi Rossi P, Carozzi F, Federici A, et al. Cervical cancer screening in women vaccinated against human papillomavirus infection: recommendations from a consensus conference. Prev Med. 2017;98:21–30.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443–8450.
   PubMed Web of Science ®Google Scholar
• Lindley MC, Jeyarajah J, Yankey D, et al. Comparing human papillomavirus vaccine knowledge and intentions among parents of boys and girls. Hum Vaccin Immunother. 2016;12:1519–1527.
   PubMed Web of Science ®Google Scholar
• Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother. 2014;10:2109–2111.
   PubMed Web of Science ®Google Scholar
• Suijkerbuijk AW, Donken R, Lugner AK, et al. The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases. Expert Rev Vaccines. 2017;16:361–375.
   PubMed Web of Science ®Google Scholar
• Bailey HH, Chuang LT, duPont NC, et al. American Society of Clinical Oncology statement: human papillomavirus vaccination for cancer prevention. J Clin Oncol. 2016;34:1803–1812.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Meites E, Unger ER. Two vs three doses of human papillomavirus vaccine: new policy for the second decade of the vaccination program. JAMA. 2016;316:2370–2372.
   PubMed Web of Science ®Google Scholar
• Noronha AS, Markowitz LE, Dunne EF. Systematic review of human papillomavirus vaccine coadministration. Vaccine. 2014;32:2670–2674.
   PubMed Web of Science ®Google Scholar
• Statement on Safety of HPV Vaccines. Global advisory committee on vaccine safety. World Health Organization (WHO); 2015 cited 2017 Jun 20. Available from: http://www.who.int/vaccine_safety/committee/GACVS_HPV_statement_17Dec2015.pdf?ua=1
   Google Scholar
• Larson H. The world must accept that the HPV vaccine is safe. Nature. 2015;528:9.
   PubMed Web of Science ®Google Scholar
• Guide to introducing HPV vaccine into national immunization programmes. World Health Organization (WHO); 2016 cited 2017 Mar 15. Available from: http://www.who.int/immunization/documents/WHO_IVB_16.02/en/
   Google Scholar
• WHO HPV Vaccine Communication. Special considerations for a unique vaccine. World Health Organization (WHO); 2016 cited 2017 Mar 15. Available from: http://apps.who.int/iris/bitstream/10665/250279/1/WHO-IVB-16.02-eng.pdf?ua=1
   Google Scholar